Keytruda was used in cominbation with a standard of care chemotherapy, then continued as a single agent every six weeks for up to 14 cycles for first-line treatment. Image credit: Shutterstock/Tada Images.

Keytruda (pembrolizumab) plus chemotherapy significantly improved progression-free survival (PFS) compared to chemotherapy alone for advanced or recurrent endometrial carcinomas, Merck has announced.

The Phase III trial (NCT03914612) involved 591 patients with stage III-IV or recurrent endometrial carcinoma – GlobalData predicts that by 2030 there will be 65,000 diagnoses in the US. It is the sixth most common cancer in women.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

“Results from this trial show that Keytruda plus chemotherapy, if approved, may represent an important new first-line immunotherapy option for patients with stage III-IV disease, and could extend the use of Keyruda to more patients earlier in their treatment journey,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer at Merck Research Laboratories.

Keytruda was used in cominbation with a standard of care chemotherapy, then continued as a single agent every six weeks for up to 14 cycles for first-line treatment.

The Keytruda regimen demonstrated a statistically significant and clinical improvement in PFS for patients, regardless of mismatch repair status. After a median follow-up of 7.9 months, Keytruda regimen significantly reduced the risk of disease progression or death by 46%. No new safety signals were identified, and adverse events occurred in 55.1% of patients taking the regimen.

“The significant improvement in progression-free survival regardless of mismatch repair status observed in this study demonstrates the potential of this pembrolizumab regimen to benefit these patients,” said Dr. Ramez Eskander, principal investigator and gynecologic oncologist at the University of California San Diego, Moores Cancer Center.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GlobalData predicts 2030 pharmaceutical market sales for endometrial cancer treatment to be $5.3bn globally.